Clinical outcome and gene- and microRNA-expression profiling according to the wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: A cancer and leukemia group B study

Haematologica

Volumn 96, Issue 10, 2011, Pages 1488-1495

  Becker, Heiko ^a   Maharry, Kati ^a,b   Radmacher, Michael D ^a,b   Mrózek, Krzysztof ^a   Metzeler, Klaus H ^a   Whitman, Susan P ^a   Schwind, Sebastian ^a   Kohlschmidt, Jessica ^a,b   Wu, Yue Zhong ^a   Powell, Bayard L ^c   Carter, Thomas H ^d   Kolitz, Jonathan E ^e   Wetzler, Meir ^f   Carroll, Andrew J ^g   Baer, Maria R ^h   Moore, Joseph O ^b   Caligiuri, Michael A ^a   Larson, Richard A ⁱ   Marcucci, Guido ^a   Bloomfield, Clara D ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF IOWA   (United States)

^e NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^f ROSWELL PARK CANCER INSTITUTE   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^h UNIVERSITY OF MARYLAND   (United States)

ⁱ UNIVERSITY OF CHICAGO   (United States)

Author keywords

Acute myeloid leukemia; Outcome; Rs16754; SNP; WT1

Indexed keywords

MICRORNA;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE; AGED; ARTICLE; ASIAN; CAUCASIAN; CONTROLLED STUDY; CYTOGENETICS; DISEASE FREE SURVIVAL; FEMALE; FLT3 GENE; GENE; GENE DUPLICATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENOTYPE; HOMOZYGOTE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NEGRO; NPM1 GENE; OVERALL SURVIVAL; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TET2 GENE; WILD TYPE; WT1 GENE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; GENE FREQUENCY; GENOTYPE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MICRORNAS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; WT1 PROTEINS; YOUNG ADULT;

EID: 80053631763     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.041905     Document Type: Article

References (37)

1. Summers K, Stevens J, Kakkas I, Smith M, Smith LL, Macdougall F, et al. Wilms' tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML. Leukemia. 2007;21 (3):550-1.
2. Paschka P, Marcucci G, Ruppert AS, Whitman SP, Mrózek K, Maharry K, et al. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2008;26(28):4595-602.
3. Virappane P, Gale RA, Hills R, Kakkas I, Summers K, Stevens J, et al. Mutations of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemoresistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol. 2008;26(33): 5429-35.
4. Renneville A, Boissel N, Zurawski V, Llopis L, Biggio V, Nibourel O, et al. Wilms tumor 1 gene mutations are associated with a high er risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association. Cancer. 2009;115(16):3719-27.
5. Becker H, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Margeson D, et al. Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 2010;116(5):788-92.
6. Hou H-A, Huang T-C, Lin L-I, Liu C-Y, Chen C-Y, Chou W-C, et al. WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system. Blood. 2010;115 (25):5222-31.
7. Gaidzik VI, Schlenk RF, Moschny S, Becker A, Bullinger L, Corbacioglu A, et al. Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. Blood. 2009;113(19): 4505-11.
8. Damm F, Heuser M, Morgan M, Yun H, Großhennig A, Göhring G, et al. Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia. J Clin Oncol. 2010;28(4):578-85.
9. Database of Single Nucleotide Polymorphisms (dbSNP). Bethesda (MD): National Center for Biotechnology Information, National Library of Medicine. dbSNP accession:rs16754, (dbSNP Build ID: 131). Available from: http://www.ncbi.nlm.nih.gov/SNP/
10. Renneville A, Boissel N, Helevaut N, Nibourel O, Terré C, Pautas C, et al. Prognostic impact of Wilms tumor 1 single nucleotide polymorphism rs16754 in older patients with acute myeloid leukemia. Blood. 2010;161(21):1113 (abstract 2701).
11. Ho PA, Kuhn J, Gerbing RB, Pollard JA, Zeng R, Miller KL, et al. WT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable- risk pediatric acute myeloid leukemia: a report from the Children's Oncology Group. J Clin Oncol. 2011;29(6):704-11.
12. Hollink IHIM, van den Heuvel-Eibrink MM, Zimmermann M, Balgobind BV, Arentsen-Peters STCJM, Alders M, et al. No prognostic impact of the WT1 gene single nucleotide polymorphism rs16754 in pediatric acute myeloid leukemia. J Clin Oncol. 2010;28 (28):e523-e6.
13. Ma W, Kantarjian H, Zhang X, Wang X, Zhang Z, Yeh C-H, et al. Mutation and single-nucleotide polymorphism (rs16754) in Wilms tumor-1 gene are independent prognostic factors in acute myeloid leukemia. Blood. 2009;114(22):413 (abstract 995).
14. Mrózek K, Carroll AJ, Maharry K, Rao KW, Patil SR, Pettenati MJ, et al. Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: the Cancer and Leukemia Group B experience. Int J Oncol. 2008;33(2):239-44.
15. Metzeler KH, Maharry K, Radmacher MD, Mrózek K, Margeson D, Becker H, et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2011;29(10): 1373-81.
16. Thiede C, Steudel C, Mohr B, Schaich M, Schäkel U, Platzbecker U, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99(12):4326-35.
17. Whitman SP, Maharry K, Radmacher MD, Becker H, Mrózek K, Margeson D, et al. FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 2010;116(18):3622-6.
18. Whitman SP, Ruppert AS, Radmacher MD, Mrózek K, Paschka P, Langer C, et al. FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood. 2008;111 (3):1552-9.
19. Döhner K, Schlenk RF, Habdank M, Scholl C, Rücker FG, Corbacioglu A, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood. 2005;106(12):3740-6.
20. Becker H, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Margeson D, et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. J Clin Oncol. 2010;28(4):596-604.
21. Marcucci G, Maharry K, Radmacher MD, Mrózek K, Vukosavljevic T, Paschka P, et al. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with highrisk molecular features: a Cancer and Leukemia Group B study. J Clin Oncol. 2008;26(31):5078-87.
22. Whitman SP, Ruppert AS, Marcucci G, Mrózek K, Paschka P, Langer C, et al. Longterm disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study. Blood. 2007;109(12):5164-7.
23. Caligiuri MA, Strout MP, Schichman SA, Mrózek K, Arthur DC, Herzig GP, et al. Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11. Cancer Res. 1996;56(6):1418-25.
24. Marcucci G, Maharry K, Wu Y-Z, Radmacher MD, Mrózek K, Margeson D, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2010;28(14):2348-55.
25. Baldus CD, Tanner SM, Ruppert AS, Whitman SP, Archer KJ, Marcucci G, et al. BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B study. Blood. 2003; 102(5):1613-8.
26. Langer C, Radmacher MD, Ruppert AS, Whitman SP, Paschka P, Mrózek K, et al. High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. Blood. 2008;111(11):5371-9.
27. Schwind S, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Holland KB, et al. BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 2010;116 (25):5660-9.
28. Marcucci G, Baldus CD, Ruppert AS, Radmacher MD, Mrózek K, Whitman SP, et al. Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J Clin Oncol. 2005;23(36):9234-42.
29. Marcucci G, Maharry K, Whitman SP, Vukosavljevic T, Paschka P, Langer C, et al. High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2007;25(22):3337-43.
30. Marcucci G, Radmacher MD, Maharry K, Mrózek K, Ruppert AS, Paschka P, et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358(18):1919-28.
31. Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol. 1990;8(5): 813-9.
32. Wouters BJ, Löwenberg B, Erpelinck- Verschueren CAJ, van Putten WLJ, Valk PJM, Delwel R. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood. 2009;113(13):3088-91.
33. Becker H, Marcucci G, Maharry K, Radmacher MD, Wu Y-Z, Mrózek K, et al. CEBPA double mutations impact favorably on the outcome of older adults with wildtype NPM1 cytogenetically normal acute myeloid leukemia and are associated with distinct gene and microRNA expression: a Cancer and Leukemia Group B study. Haematologica. 2010;95(suppl 2):247-8 (abstract 593).
34. Damm F, Heuser M, Ganser A, Krauter J. Reply to I.H.I.M. Hollink et al. J Clin Oncol. 2010;28(28):e527-e8.
35. Sekeres MA, Peterson B, Dodge RK, Mayer RJ, Moore JO, Lee EJ, et al. Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. Blood. 2004;103(11):4036-42.
36. Byrne MM, Halman LJ, Koniaris LG, Cassileth PA, Rosenblatt JD, Cheung MC. Effects of poverty and race on outcomes in acute myeloid leukemia. Am J Clin Oncol. 2011;34(3):297-304.
37. Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-74.